Literature DB >> 23817438

Amyloid deposition and cognition in older adults: the effects of premorbid intellect.

Kevin Duff1, Norman L Foster, Kathryn Dennett, Dustin B Hammers, Lauren V Zollinger, Paul E Christian, Regan I Butterfield, Britney E Beardmore, Angela Y Wang, Kathryn A Morton, John M Hoffman.   

Abstract

Although amyloid deposition remains a marker of the development of Alzheimer's disease, results linking amyloid and cognition have been equivocal. Twenty-five community-dwelling non-demented older adults were examined with (18)F-flutemetamol, an amyloid imaging agent, and a cognitive battery, including an estimate of premorbid intellect and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). In the first model, (18)F-flutemetamol uptake significantly correlated with the Delayed Memory Index of the RBANS (r = -.51, p = .02) and premorbid intellect (r = .43, p = .03). In the second model, the relationship between (18)F-flutemetamol and cognition was notably stronger when controlling for premorbid intellect (e.g., three of the five RBANS Indexes and its Total score significantly correlated with (18)F-flutemetamol, r's = -.41 to -.58). Associations were found between amyloid-binding (18)F-flutemetamol and cognitive functioning in non-demented older adults. These associations were greatest with delayed memory and stronger when premorbid intellect was considered, suggesting that cognitive reserve partly compensates for the symptomatic expression of amyloid pathology in community-dwelling elderly.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Neuroimaging; Neuropsychology; Premorbid intellect

Mesh:

Substances:

Year:  2013        PMID: 23817438      PMCID: PMC3807831          DOI: 10.1093/arclin/act047

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  21 in total

Review 1.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

2.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging.

Authors:  Christopher C Rowe; Kathryn A Ellis; Miroslava Rimajova; Pierrick Bourgeat; Kerryn E Pike; Gareth Jones; Jurgen Fripp; Henri Tochon-Danguy; Laurence Morandeau; Graeme O'Keefe; Roger Price; Parnesh Raniga; Peter Robins; Oscar Acosta; Nat Lenzo; Cassandra Szoeke; Olivier Salvado; Richard Head; Ralph Martins; Colin L Masters; David Ames; Victor L Villemagne
Journal:  Neurobiol Aging       Date:  2010-05-15       Impact factor: 4.673

3.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

4.  A life course model of cognitive activities, socioeconomic status, education, reading ability, and cognition.

Authors:  Angela L Jefferson; Laura E Gibbons; Dorene M Rentz; Janessa O Carvalho; Jennifer Manly; David A Bennett; Richard N Jones
Journal:  J Am Geriatr Soc       Date:  2011-07-28       Impact factor: 5.562

5.  Predicting premorbid memory functioning in older adults.

Authors:  Kevin Duff
Journal:  Appl Neuropsychol       Date:  2010-10

6.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

7.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

8.  Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.

Authors:  Catherine M Roe; Mark A Mintun; Gina D'Angelo; Chengjie Xiong; Elizabeth A Grant; John C Morris
Journal:  Arch Neurol       Date:  2008-11

9.  Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition.

Authors:  Prashanthi Vemuri; Stephen D Weigand; Scott A Przybelski; David S Knopman; Glenn E Smith; John Q Trojanowski; Leslie M Shaw; Charlie S Decarli; Owen Carmichael; Matt A Bernstein; Paul S Aisen; Michael Weiner; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2011-04-07       Impact factor: 13.501

10.  Cognition, reserve, and amyloid deposition in normal aging.

Authors:  Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

View more
  14 in total

1.  Amyloid Positivity Using [18F]Flutemetamol-PET and Cognitive Deficits in Nondemented Community-Dwelling Older Adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Kevin P Horn; Kelli M Rasmussen; Britney E Beardmore; Lance D Burrell; Kevin Duff; John M Hoffman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2017-04-12       Impact factor: 2.035

2.  Long-term Changes in 18F-Flutemetamol Uptake in Nondemented Older Adults.

Authors:  Kevin Duff; Kevin P Horn; John M Hoffman
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Apr-Jun       Impact factor: 2.703

3.  External validation of change formulae in neuropsychology with neuroimaging biomarkers: A methodological recommendation and preliminary clinical data.

Authors:  Kevin Duff; Kayla R Suhrie; Bonnie C A Dalley; Jeffrey S Anderson; John M Hoffman
Journal:  Clin Neuropsychol       Date:  2018-06-08       Impact factor: 3.535

4.  Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Britney E Beardmore; Lance D Burrell; Kevin P Horn; Kelli M Rasmussen; Norman L Foster; Kevin Duff; John M Hoffman
Journal:  Clin Neuropsychol       Date:  2017-01-12       Impact factor: 3.535

Review 5.  Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.

Authors:  Kerstin Heurling; Antoine Leuzy; Eduardo R Zimmer; Mark Lubberink; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-06       Impact factor: 9.236

6.  The interactive effects of age, education, and BMI on cognitive functioning.

Authors:  Joshua W Kirton; Vonetta M Dotson
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2015-09-01

7.  Short-Term Practice Effects and Amyloid Deposition: Providing Information Above and Beyond Baseline Cognition.

Authors:  K Duff; D B Hammers; B C A Dalley; K R Suhrie; T J Atkinson; K M Rasmussen; K P Horn; B E Beardmore; L D Burrell; N L Foster; J M Hoffman
Journal:  J Prev Alzheimers Dis       Date:  2017

Review 8.  Amyloid imaging in Alzheimer's disease: a literature review.

Authors:  P Saidlitz; T Voisin; B Vellas; P Payoux; A Gabelle; M Formaglio; J Delrieu
Journal:  J Nutr Health Aging       Date:  2014-07       Impact factor: 4.075

9.  Validation of one-week reliable change methods in cognitively intact community-dwelling older adults.

Authors:  Dustin B Hammers; Kayla R Suhrie; Ava Dixon; Sariah Porter; Kevin Duff
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2020-07-02

10.  Relationship between a novel learning slope metric and Alzheimer's disease biomarkers.

Authors:  Dustin B Hammers; Kayla Suhrie; Ava Dixon; Brian D Gradwohl; Zane G Archibald; Jace B King; Robert J Spencer; Kevin Duff; John M Hoffman
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.